JPMorgan Chase & Co. Analysts Give AstraZeneca (LON:AZN) a £125 Price Target

AstraZeneca (LON:AZNGet Rating) received a £125 ($151.04) target price from investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 23.49% from the company’s current price.

A number of other equities research analysts have also issued reports on the company. Jefferies Financial Group set a GBX 9,800 ($118.41) target price on AstraZeneca in a research report on Wednesday, September 14th. Credit Suisse Group downgraded AstraZeneca to a “neutral” rating and set a £110 ($132.91) price objective on the stock. in a report on Thursday. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Monday, September 5th. Barclays restated an “overweight” rating and set a £125 ($151.04) price target on shares of AstraZeneca in a report on Thursday. Finally, Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, July 12th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from, the company currently has an average rating of “Moderate Buy” and an average price target of £108.05 ($130.55).

AstraZeneca Stock Performance

LON:AZN opened at £101.22 ($122.31) on Monday. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 87.31. The company has a 50-day moving average of £108.38 and a 200-day moving average of £104.26. AstraZeneca has a twelve month low of GBX 8,029 ($97.02) and a twelve month high of £115.40 ($139.44). The firm has a market cap of £156.84 billion and a price-to-earnings ratio of -172.14.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.